West Paces Advisors Inc. Abb Vie Inc. Transaction History

West Paces Advisors Inc.

$408 Billion
Q3 2024

A detailed history of West Paces Advisors Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, West Paces Advisors Inc. holds 9,548 shares of ABBV stock, worth $1.59 Million. This represents 0.46% of its overall portfolio holdings.

Number of Shares

9,548

Previous 9,792 2.49%

Holding current value

$1.59 Million

Previous $1.68 Billion 12.27%

% of portfolio

0.46%

Previous 0.44%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 15, 2024	SELL	$163.84 - $199.33 $39,976 - $48,636	-244 Reduced 2.49%	9,548 $1.89 Billion
Q2 2024 Jul 16, 2024	SELL	$154.79 - $180.76 $8,513 - $9,941	-55 Reduced 0.56%	9,792 $1.68 Billion
Q1 2024 Apr 15, 2024	SELL	$159.82 - $182.1 $48,904 - $55,722	-306 Reduced 3.01%	9,847 $1.79 Billion
Q4 2023 Jan 30, 2024	BUY	$137.6 - $154.97 $54,902 - $61,833	399 Added 4.09%	10,153 $1.57 Billion
Q3 2023 Dec 18, 2023	SELL	$133.59 - $154.65 $3,206 - $3,711	-24 Reduced 0.25%	9,754 $1.45 Billion
Q2 2023 Dec 18, 2023	BUY	$132.51 - $164.9 $7,155 - $8,904	54 Added 0.56%	9,778 $1.32 Billion
Q1 2023 Dec 18, 2023	BUY	$144.61 - $166.54 $36,152 - $41,635	250 Added 2.64%	9,724 $1.55 Billion
Q4 2022 Dec 18, 2023	BUY	$138.31 - $165.87 $1.31 Million - $1.57 Million	9,474 New	9,474 $1.53 Billion
Q3 2022 Dec 18, 2023	SELL	$134.21 - $153.93 $4,831 - $5,541	-36 Reduced 0.38%	9,527 $1.28 Billion
Q2 2022 Dec 18, 2023	BUY	$137.62 - $174.96 $28,762 - $36,566	209 Added 2.23%	9,563 $1.46 Billion
Q1 2022 Dec 18, 2023	SELL	$131.98 - $163.75 $52,791 - $65,500	-400 Reduced 4.1%	9,354 $1.52 Billion
Q4 2021 Dec 19, 2023	BUY	$107.43 - $135.93 $39,211 - $49,614	365 Added 3.88%	9,774 $1.32 Billion
Q3 2021 Dec 19, 2023	BUY	$106.4 - $120.78 $744 - $845	7 Added 0.07%	9,409 $1.01 Billion
Q2 2021 Dec 19, 2023	SELL	$105.21 - $117.21 $35,876 - $39,968	-341 Reduced 3.5%	9,402 $1.06 Billion
Q1 2021 Dec 19, 2023	BUY	$102.3 - $112.62 $51,866 - $57,098	507 Added 5.49%	9,743 $1.05 Billion
Q4 2020 Dec 19, 2023	BUY	$80.49 - $108.67 $76,143 - $102,801	946 Added 11.41%	9,236 $990 Million
Q3 2020 Dec 19, 2023	SELL	$85.91 - $100.83 $3,522 - $4,134	-41 Reduced 0.49%	8,290 $726 Million
Q2 2020 Dec 19, 2023	SELL	$73.37 - $98.18 $104,405 - $139,710	-1,423 Reduced 14.59%	8,331 $818 Million
Q1 2020 Dec 20, 2023	SELL	$64.5 - $97.79 $527,803 - $800,215	-8,183 Reduced 71.16%	3,316 $253 Million
Q4 2019 Dec 21, 2023	BUY	$72.13 - $90.25 $30,438 - $38,085	422 Added 46.12%	1,337 $118 Million
Q3 2019 Dec 21, 2023	SELL	$62.98 - $75.72 $122,370 - $147,123	-1,943 Reduced 67.98%	915 $69.3 Million
Q2 2019 Dec 21, 2023	SELL	$65.7 - $83.98 $38,631 - $49,380	-588 Reduced 17.06%	2,858 $208 Million
Q1 2019 Dec 21, 2023	SELL	$77.14 - $90.79 $606,320 - $713,609	-7,860 Reduced 69.52%	3,446 $278 Million
Q4 2018 Dec 21, 2023	SELL	$77.85 - $96.01 $50,291 - $62,022	-646 Reduced 5.4%	11,306 $1.04 Billion
Q3 2018 Dec 20, 2023	BUY	$88.91 - $98.84 $155,147 - $172,475	1,745 Added 17.89%	11,499 $1.09 Billion
Q2 2018 Dec 21, 2023	BUY	$89.78 - $106.23 $32,859 - $38,880	366 Added 3.16%	11,952 $1.11 Billion
Q1 2018 Dec 21, 2023	BUY	$92.01 - $123.21 $40,576 - $54,335	441 Added 3.96%	11,586 $1.1 Billion
Q4 2017 Dec 21, 2023	BUY	$89.56 - $98.21 $89,918 - $98,602	1,004 Added 9.9%	11,145 $1.08 Billion
Q3 2017 Dec 21, 2023	BUY	$69.85 - $89.22 $81,026 - $103,495	1,160 Added 12.92%	10,141 $901 Million
Q2 2017 Dec 21, 2023	BUY	N/A	27 Added 0.3%	8,981 $651 Million
Q1 2017 Dec 21, 2023	BUY	N/A	1,031 Added 13.01%	8,954 $583 Million
Q4 2016 Dec 21, 2023	SELL	N/A	-1,831	7,923 $496 Million

Others Institutions Holding ABBV

# of Institutions

3,846

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $295B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of West Paces Advisors Inc., based on Form 13F filings with the SEC.

News

Stay updated on West Paces Advisors Inc. with notifications on news.

Account

West Paces Advisors Inc. Abb Vie Inc. Transaction History